{
    "clinical_study": {
        "@rank": "104250", 
        "arm_group": [
            {
                "arm_group_label": "FDC YH16410", 
                "arm_group_type": "Experimental", 
                "description": "Drug: Test treatment: FDC YH16410 (Telmisartan 80mg/ Rosuvastatin 20mg).\nSubjects will receive single oral dose of 1 tablet of FDC containing Telmisartan 80mg and Rosuvastatin 20mg in fasted state"
            }, 
            {
                "arm_group_label": "Co-administration", 
                "arm_group_type": "Active Comparator", 
                "description": "Drug: Reference Treatment: Co-administration(Telmisartan 80mg and Rosuvastatin 20mg).\nSubjects will receive 1 x Telmisartan 80mg with 1 x Rosuvastatin 20mg tablet administered orally in fasted state as a single dose"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a 2 by 2 cross-over study to evaluate pharmacokinetics of telmisartan and\n      rosuvastatin FDC compared to reference telmisartan and rosuvastatin coadministered in two\n      groups enrolling healthy adult male and female subjects under fasting conditions.\n\n      Subjects will be admitted to the clinic in the evening before Day 1. All subjects will\n      receive a single oral dose of telmisartan/rosuvastatin FDC or telmisartan and rosuvastatin\n      co-administered in the morning on Day 1. All the subjects will remain in the clinical unit\n      until completion of all assessments  on Day 2 including collection post-dose PK sample.\n      Subjects will return to the clinic for pharmacokinetic samples at scheduled time.\n\n      The two treatment periods will be separated by a washout period."
        }, 
        "brief_title": "PK Study of Telmisartan/Rosuvastatin FDC Compared to Combination of Telmisartan and Rosuvastatin", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Dyslipidemia & Hypertension", 
        "condition_browse": {
            "mesh_term": [
                "Hypertension", 
                "Dyslipidemias"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy male and female aged 20 to 50 with a body mass index(BMI) between 18.5 and 25\n             kg/m2\n\n          2. Acceptable medical history, physical examination, laboratory tests and EKG, during\n             screening\n\n          3. Provision of signed written informed consent 20~50 yrs old, healthy Korean Subjects\n\n        Exclusion Criteria:\n\n          1. History of and clinically significant disease\n\n          2. Sitting blood pressure meeting the following criteria at screening: 150 \u2265 systolic\n             blood pressure \u2264100 (mmHg) and 100 \u2265 diastolic blood pressure \u2264 65 (mmHg) amd 100 \u2265\n             Heart rate \u2264 40\n\n          3. A history of drug abuse or the presence of positive reactions to drugs that have\n             abuse potential in urine screenings for drugs.\n\n          4. Administration of other investigational products within 90 days prior to the first\n             dosing.\n\n          5. Administration of herbal medicine within 28 days or administration of ethical drugs\n             within 14 days or administration of over-the-counter (OTC) drugs within 7 days prior\n             to the first dosing of the investigational product (if the investigator (study\n             doctor) determines that the person meets other criteria appropriately, the relevant\n             person may participate in the study).\n\n          6. Have AST(SGOT) or/and ALT(SGPT) > 3 times of normal upper limit at the time of\n             screening\n\n          7. Volunteers considered not eligible for the clinical trial by the investigator (study\n             doctor) due to reasons including laboratory test results, ECGs, or vital signs."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "185", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01975961", 
            "org_study_id": "YH16410-102"
        }, 
        "intervention": {
            "arm_group_label": [
                "FDC YH16410", 
                "Co-administration"
            ], 
            "description": "For co-administration, Crestor 1 tablet and Micardis 1 tablet. For FDC administration, FDC 1 tablet.", 
            "intervention_name": "Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg) , FDC", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Telmisartan", 
                "Rosuvastatin", 
                "Benzoates"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 28, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Severance Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-label, Single-dose, 2-way Cross-over Study to Compare the Safety and the Pharmacokinetic Characteristics of the Co-administration of Telmisartan and Rosuvastatin and YH16410 in Healthy Volunteers", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "plasma pharmacokinetic parameters for telmisartan and rosuvastatin in relevant treatments", 
            "safety_issue": "No", 
            "time_frame": "0~72hr, 17points"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01975961"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Yuhan Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yuhan Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}